Researchers aim to improve chemotherapy by enhancing drug efficacy and reducing heart toxicity through dual activation of CAR and Nrf2 pathways.

Paul Shapiro, PhD, and Jeffrey Hasday, MD, are developing a class of drugs that may be able to reset the natural balance of inflammation and prevent a number of serious diseases.

Allan Doctor, MD, of the School of Medicine and Joga Gobburu, PhD, MBA, of the School of Pharmacy are optimistic they are on the cusp of developing the world’s first viable artificial blood.

New study sheds light on how disease progression and biomolecular corona affect nanoparticle-mediated immune activation.

Research from the lab of Jana Shen looks at a mutation causing diminished effectiveness of Paxlovid.

Regulatory science center will receive up to $50 million over five years.

Aziza Frank is a PhD candidate in the Department of Pharmaceutical Sciences.

School received more than $25 million for research in the fiscal year 2022.

Event enhances collaboration between two Baltimore institutions.

PSC faculty member to oversee growth of the School’s $38.5 million research portfolio.

Toxic metal found naturally is associated with variety of diseases.

Ester Villalonga Olives, PhD, MsC, is in the first cohort of a new program for junior faculty of diverse backgrounds.